Ocugen exceeded revenue expectations in Q4, despite a loss; received FDA clearance for COVID-19 vaccine.

From StockTwits: 2025-03-05 21:12:13

Stocktwits users are optimistic about Ocugen, Inc.’s pipeline and its goal of securing three BLAs in the next three years. The company’s stock initially dropped 2.8% but recovered in extended trading after exceeding revenue expectations in its quarterly earnings report. Despite a fourth-quarter loss of $0.05 per share, revenue was $764,000, higher than expected. Ocugen’s gene therapy platform includes treatments for eye diseases like retinitis pigmentosa and dry age-related macular degeneration. The company recently received FDA clearance for an inhaled mucosal COVID-19 vaccine. Ocugen secured $65 million in financing to support ongoing clinical trials and extend its cash runway. Sentiment on Stocktwits is bullish, with message volume increasing. Retail traders are hopeful about the company’s future despite facing a significant short interest rate and trading below analyst price targets. Shares of Ocugen are down over 33% year-to-date.



Read more at StockTwits: Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates